Ultragenyx Pharmaceutical Inc(RARE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.84 | Insider Own | 8.51% | Shs Outstand | 98.3M | Perf Week | 4.56% |
| Market Cap | 1.65B | Forward P/E | - | EPS next Y | 85.93% | Insider Trans | -0.46% | Shs Float | 90.2M | Perf Month | 16.24% |
| Enterprise Value | 2.56B | PEG | - | EPS next Q | -1.1 | Inst Own | 111.79% | Short Float | 22.34% | Perf Quarter | -33% |
| Income | -0.59B | P/S | 2.3 | EPS this Y | 21.1% | Inst Trans | 4.18% | Short Ratio | 4.9 | Perf Half Y | -31.72% |
| Sales | 0.72B | P/B | - | EPS next 5Y | - | ROA | -45.63% | Short Interest | 20.15M | Perf YTD | -27.17% |
| Book/sh | -2.96 | P/C | 5.49 | EPS past 3/5Y | 16.78% -13.72% | ROE | -656.54% | 52W High | -58.01% ($39.89) | Perf Year | -52.56% |
| Cash/sh | 3.05 | P/FCF | - | Sales past 3/5Y | 22.81% 19.95% | ROIC | -70.23% | 52W Low | 31.58% ($12.73) | Perf 3Y | -48.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.66% | Gross Margin | 78.47% | Volatility(W/M) | 4.25% 5.04% | Perf 5Y | -79.49% |
| Dividend TTM | - | EV/Sales | 3.57 | Sales Y/Y TTM | 17.5% | Oper. Margin | -73.77% | ATR (14) | 0.83 | Perf 10Y | -73.32% |
| Dividend Ex-Date | - | Quick Ratio | 1.56 | EPS Q/Q | 22.67% | Profit Margin | -81.79% | RSI (14) | 56.43 | Recom | 2.05 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.73 | Sales Q/Q | 28.53% | SMA20 | 9.52% ($15.29) | Beta | 0.38 | Target Price | $26.25 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/3 | SMA50 | -4.57% ($17.55) | Rel Volume | 1.2 | Prev Close | $16.08 |
| Employees | 1371 | LT Debt/Eq | - | EPS/Sales Surpr. | 26.08% 16.89% | SMA200 | -27.2% ($23.01) | Avg Volume(3M) | 4.12M | Price | $16.75 |
| IPO | 2014/1/31 | Option/Short | Yes/Yes | Trades | 23479 | Volume | 4,943,020 | Change | 4.17% |
🧬 A U.S. biopharmaceutical company that develops and commercializes treatments for rare and ultra-rare genetic diseases. It has a diversified pipeline—including marketed products and gene therapies—targeting rare genetic diseases with high unmet need, and is building a differentiated position as a rare-disease-focused biopharma with deep expertise and a broad pipeline in the rare disease field.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded about as much as usual. That is 120% of its average volume.
Next earnings report: November 3
6 days to go.
RARE has a sound balance sheet but weak earning power
Of every $100 in sales, $73.77 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +21.1% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $230. Peers typically go for $1,261.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -79.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
TMFS Motley Fool Small-Cap Growth ETF 0.03% 
GNOM Global X Genomics & Biotechnology ETF 0.02% 
BBP Virtus Biotech ETF 0.01% 
XBI State Street SPDR S&P Biotech ETF 0.01% 
HAPS Harbor Human Capital Factor US Small Cap ETF 0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
REMX VanEck Rare Earth/Strategic Metals ETF 1.5B 
REXC Sprott Rare Earths Ex-China ETF 67M 
EART Global X Rare Earth & Critical Materials ETF 42M 
EMET VanEck Copper and Electrification Metals ETF 31M 
FMTL First Trust Indxx Critical Metals ETF 29M It ranks #121 of 594 in the industry
Based on market cap of $2B.
URGN#119 UroGen Pharma Ltd $2B PER - 
NVAX#120 Novavax Inc $2B PER - RARE#121 Ultragenyx Pharmaceutical Inc $2B PER - 
IMCR#122 Immunocore Holdings plc ADR $2B PER - 
TRAX#123 First Tracks Biotherapeutics Inc $2B PER - 
FAQ
What kind of company is RARE?
RARE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RARE?
The market cap of RARE is approximately $1.7B, ranking 2,219 within its sector.
What is the 52-week high and low for RARE?
RARE has recorded a 52-week high of $39.89 and a low of $12.73.
